- Home
- BSY vs EXEL Comparison
BSY vs EXEL Comparison
Compare BSY & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BSY | EXEL |
|---|---|---|
| Founded | 1984 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 11.1B |
| IPO Year | 2002 | 2000 |
Fundamental Metrics
Financial Performance| Metric | BSY | EXEL |
|---|---|---|
| Price | $34.03 | $44.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 21 |
| Target Price | ★ $52.33 | $46.60 |
| AVG Volume (30 Days) | ★ 3.0M | 2.5M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | 0.67 | ★ 2.78 |
| Revenue | ★ $734,849,000.00 | $452,477,000.00 |
| Revenue This Year | $11.37 | $13.66 |
| Revenue Next Year | $10.42 | $14.30 |
| P/E Ratio | $51.01 | ★ $15.90 |
| Revenue Growth | ★ 6.24 | N/A |
| 52 Week Low | $30.97 | $32.38 |
| 52 Week High | $59.25 | $48.74 |
Technical Indicators
Market Signals| Indicator | BSY | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 40.96 | 54.59 |
| Support Level | $32.84 | $43.20 |
| Resistance Level | $35.04 | $44.67 |
| Average True Range (ATR) | 1.35 | 1.46 |
| MACD | 0.18 | 0.16 |
| Stochastic Oscillator | 67.88 | 88.98 |
Price Performance
Historical ComparisonAbout BSY Bentley Systems Incorporated Class B
Bentley Systems is a software vendor that caters to civil engineers, constructors, and geospatial professionals by enabling design, simulation, and data management of infrastructure assets such as roads and bridges. While Bentley is smaller than many other design software companies, it is a market leader across a handful of specialty areas, including public works, electricity grids, and transit.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.